Ventiv will also provide Boehringer Ingelheim with a full suite of sales and marketing services to support this expanded sales effort. Boehringer Ingelheim, headquartered in Ingelheim, Germany, operates globally with 144 affiliates in 45 countries and nearly 36,000 employees.
“Ventiv is a very client-focused organization and has worked closely with us to provide a variety of business solutions to achieve our goals. We are pleased to be working with them again as our partner of choice for this important initiative,” said Mike Leonetti, head of alliances and partnerships for Boehringer.
In other news, Boehringer recently announced that the European Medicines Agency issued a positive opinion recommending approval of the company’s investigational drug Sifrol/Mirapexin (pramipexole) for the treatment of restless legs syndrome in the European Union.